ERBB2 and gastroesophageal junction adenocarcinoma: Trastuzumab emerged as a safe and effective treatment alternative for patients with advanced gastric or GEJ adenocarcinoma featuring HER2 overexpression, based on the outcomes of the randomized Phase III ToGA trial [24].